期刊文献+

CpG ODN协同MAGE-3抗原肽致敏DC疫苗对膀胱癌细胞BIU-87的抑制作用 被引量:1

Inhibitory effects of DC vaccine sensitized with MAGE-3 combined with CpG ODN on bladder cancer BIU-87 cells
下载PDF
导出
摘要 目的:探讨含未甲基化胞嘧啶鸟嘌呤(CpG)序列的细菌寡核苷酸(CpG oligodeoxynucleotide,CpG ODN)免疫佐剂在增强黑色素瘤抗原基因-3(melanoma antigen gene-3,MAGE-3)抗原肽致敏DC抗膀胱肿瘤细胞的作用及其分子机制。方法:采用Ficoll法从健康志愿者HLA-A2型外周血中分离单个核细胞,常规方法诱导培养制备成熟DC。MTT法检测不同方式(MAGE-3、CpG ODN、MAGE-3+CpG ODN和无关抗原对照)致敏DC对T淋巴细胞增殖和CTL对靶细胞BIU-87的杀伤作用。CpG ODN+MAGE-3抗原肽致敏DC抗裸鼠BIU-87膀胱癌细胞移植瘤治疗7、11 d测定移植瘤质量变化,MTT和Western blotting法分别检测移植瘤细胞的增殖水平及其凋亡蛋白表达的变化。结果:CpG ODN+MAGE-3抗原肽致敏DC能够促进T淋巴细胞增殖(P<0.05),并显著提高活化T淋巴细胞的CTL对靶细胞BIU-87的杀伤活性(P<0.05)。体内实验表明,致敏DC治疗7、11 d的各组移植瘤质量均明显降低(均P<0.05),移植瘤的增殖能力下降也较明显(P<0.05);与其他致敏DC方式相比较,尤以CpG ODN+MAGE-3致敏DC组在治疗11 d时的移植瘤质量降低非常显著(P<0.01),且明显促进荷瘤小鼠脾脏单个核细胞的增殖能力(P<0.01);该组在治疗第3天起移植瘤组织Bcl-2表达水平明显降低、Bax水平明显升高(均P<0.05或P<0.01)。结论:CpG ODN能促进MAGE-3抗原肽致敏DC对膀胱癌BIU-87细胞的抑制作用,为膀胱癌DC疫苗的临床应用提供了实验依据。 Objective: To investigate the role of CpG ODN(CpG oligodeoxynucleotide) adjuvant in enhancing the anti-bladder cancer response induced by MAGE-3(melanoma antigen gene-3) antigen and its molecular mechanism. Methods: Mononuclear cells were isolated from HLA-A2 type peripheral blood of healthy donors by Ficoll method to prepare mature DC by conventional means. DC surface markers were detected by flow cytometry. MTT assay was used to detect the promotion effect of DCs sensitized by different means(MAGE-3, CpGODN, MAGE-3+CpG ODN, irrelevant control antigen) on the proliferation of T lymphocytes and the killing effect of CTL on BIU-87 tumor cells. The tumor mass of nude mice bearing BIU-87 bladder cell xenograft were examined on Day 7 and 11 after CpG ODN+MAGE-3 sensitized DC treatment. The expression of Bcl-2/Bax protein was detected by Western blotting while the proliferation level of xenograft cells was detected by MTT assay. Results: DCs sensitized by CpG ODN combined with MAGE-3 antigenic peptides could promote the proliferation of T lymphocytes and significantly enhance the killing effect of CTL on target BIU-87 cells(P〈0.05). Compared with other sensitized DCs, in vivo experiments showed that 7 and 11 days after treatment, both the tumor volume and weight were significantly reduced(all P〈0.05), and the proliferation ability of xenograft tumor was decreased(P〈0.05). Compared withother sensitization means, CpG ODN+MAGE-3 especially exhibited obvious inhibitive effect on tumor growth on Day 11, and significantly promoted the proliferation of splenic monocytes of tumor bearing mice(P〈0.01); moreover, Bcl-2 expression in xenograft tissues significantly decreased(P〈0.01)while Bax expression significantly increased(P〈0.05 or P〈0.01)on Day 3 after treatment. Conclusion: CpG ODN can promote the inhibitory effect of MAGE-3 sensitized DC on bladder cancer BIU-87 cells, which will provide experimental basis for clinical application of DC vaccine in bladder can
作者 李秀真 薛庆节 路海 聂尚丹 王晖 李运清 赵龙玉 谭文彬 LI Xiuzhen, XUE Qingjie, LU Hai, NIE Shangdan, WANG Hui, LI Yunqing, ZHAO Longyu, TAN Wenbing(Department of Pathogenic Biology of Jining Medical College, Jining 272000, Shandong, China)
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2018年第9期891-897,共7页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(No.31500056) 山东省高等学校科技计划资助项目(No.J11LF03) 济宁市科技助推新旧动能转换计划资助项目(No.2017SMNS001) 济宁医学院青年教师科研扶持基金资助项目(JNo.Y2017KJ010)~~
关键词 膀胱癌 BIU-8细胞 树突状细胞 含CpG序列的细菌寡核苷酸 黑色素瘤抗原基因-3 bladder cancer BIU-87 cell dendritic cell (DC) CpG oligodeoxynucleotide (CpG ODN) melanoma antigen gene-3(MAGE-3)
  • 相关文献

参考文献4

二级参考文献149

  • 1姜宝法,刘春晓,崔永春,徐涛,徐敏,王家林,杜君.EORTCQLQ-C30的信度、效度研究[J].中国临床心理学杂志,2005,13(1):31-32. 被引量:121
  • 2Topalian SL, Weiner GJ, Pardoll OM. Cancer immunotherapy comes of age[J]. J Clin Oncol, 2011, 29 (36): 4828-4836. 被引量:1
  • 3Slingluff CL Ir, Petroni GR, Chianese Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multi peptide vaccines for melanoma in the adjuvant setting[J]. Clin Cancer Res, 2007, 13(21): 6386-6395. 被引量:1
  • 4Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule[J]. J Clin Oncol, 2004, 22(22): 4474-4485. 被引量:1
  • 5Wang Y, Han KJ, Pang XW, et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies[J]. J Immunol, 2002, 169(2): 1102-1109. 被引量:1
  • 6Li B, Wang Y, Chen J, et al. Identification of a new HLA - A * 0201-restricted CD8 + T cell epitope from hepatocellular carcinoma-associated antigen HCA587[J]. Clin Exp Immunol, 2005, 140 (2): 310-319. 被引量:1
  • 7Xing Q, Pang XW, Peng JR, et al. Identification of new cytotoxic T -lymphocyte epitopes from cancer testis antigen HCA587[J]. Biochem Biophys Res Commun, 2008, 372 (2): 331-335. 被引量:1
  • 8Davila E, Celis E. Repeated administration of cytosinephosphorothiolated guanine-containing oligonu?cleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity[J]. J Immunol, 2000,165 (1): 539-547. 被引量:1
  • 9Klinman OM. Immunotherapeutic uses of CpG oligodeoxynucleotides[J]. Nat Rev Immunol, 2004, 4(4): 249-258. 被引量:1
  • 10Miconnet I, Koenig S, Speiser D, et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide[J]. J Immunol, 2002, 168(3): 1212-1218. 被引量:1

共引文献60

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部